Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.84 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.84 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.84 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.84 |
| ▸ | SRC | P12931 | 1/20 | 0.84 |
| ▸ | DDX6 | P26196 | 1/20 | 0.84 |
| ▸ | PDE4A | P27815 | 1/20 | 0.84 |
| ▸ | CSK | P41240 | 1/20 | 0.84 |
| ▸ | MTOR | P42345 | 1/20 | 0.84 |
| ▸ | PLK1 | P53350 | 1/20 | 0.84 |
| ▸ | PRKDC | P78527 | 1/20 | 0.84 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.84 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.84 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.84 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.72 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348187 | 1.00 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL4348197 | 1.00 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL29361545 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL1812377 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL4353531 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL25360577 | 0.91 | PIK3CA (0.84) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL825695 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL30336052 | 0.89 | PIK3CA (0.69) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL25532385 | 0.89 | PIK3CA (0.69) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL25532391 | 0.89 | PIK3CA (0.69) | PIK3CBPIK3CAPIK3CDPIK3CGSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4646626-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | claimed |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-1611109-A4 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | EP | claimed |
| CN-101260104-A | Inhibition of phosphoinositide 3-kinase beta | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | claimed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | claimed |
| JP-2006522109-A | — | — | 2006-09-28 | — | — | JP | claimed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | claimed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| US-20230226070-A1 | TREATMENT OF THROMBOSIS AND ASSOCIATED DISORDERS WITH AN ANTI-PLATELET AGENT. | THE HEART RESEARCH INSTITUTE LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| CN-116171157-A | Treatment of thrombosis and related disorders using antiplatelet agents | 心脏研究所有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | disclosed |
| CN-1688575-A | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD (AU) | 2005-10-26 | — | — | CN | disclosed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | PIK3CB 769/4885PIK3CA 426/4885PIK3CD 1353/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | PIK3CB 1318/4885PIK3CA 1228/4885PIK3CD 2515/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PIK3CB 8/4885PIK3CA 16/4885PIK3CD 15/4885 |
| US-20230226070-A1 | TREATMENT OF THROMBOSIS AND ASSOCIATED DISORDERS WITH AN ANTI-PLATELET AGENT. | PLAT, PLA2G7, PIK3R5 | PIK3CB 38/4885PIK3CA 17/4885PIK3CD 23/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | PIK3CB 769/4885PIK3CA 426/4885PIK3CD 1353/4885 |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ITK, PI4KA, PIK3CA | PIK3CB 9/4885PIK3CA 3/4885PIK3CD 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.